Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 11/20 | 0.38 |
| ▸ | ESR1 | P03372 | 9/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | NMT1 | P30419 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6041733 | 1.00 | ESR2 (0.38) | ESR2ESR1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2685848 | 0.91 | ESR1 (0.34) | ESR2ESR1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL6041790 | 0.91 | ESR1 (0.34) | ESR2ESR1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL6042353 | 0.80 | S1PR5 (0.49) | RAB9A | |
| SCHEMBL6042358 | 0.80 | S1PR5 (0.49) | RAB9A | |
| SCHEMBL6043559 | 0.78 | ESR2 (0.36) | ESR2ESR1GRIN2BUSP30 | |
| SCHEMBL6043554 | 0.78 | ESR2 (0.36) | ESR2ESR1GRIN2BUSP30 | |
| SCHEMBL6043970 | 0.78 | HDAC4 (0.39) | CYP2C9CYP3A4CYP2D6NMT1 | |
| SCHEMBL23148291 | 0.75 | USP30 (0.47) | ESR2ESR1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL29450234 | 0.75 | NMT2 (0.42) | NMT1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | ESR2 696/4885ESR1 2390/4885CYP2C9 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.